Global Newborn Screening Market 2023-2030

Global Newborn Screening Market 2023-2030

Global Newborn Screening Market Size, Share & Trends Analysis Report by Technology (Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry (LC-MS/MS), Pulse Oximetry, DNA Microarrays and Next-Generation Sequencing (NGS), Enzyme Based Assays, and Others), by Test Type (Blood Spot Screening, Hearing Screening, Pulse Oximetry Screening, Critical Congenital Heart Defect (CCHD), and Others), and by End-User (Hospitals and Birthing Centers, Neonatal Intensive Care Units (NICUs), Diagnostic Centers, Researchers and Scientists, and Others) Forecast Period (2023-2030)

The global newborn screening market is anticipated to grow at a CAGR of 7.8% during the forecast period (2023-2030). The market’s growth is attributed to early intervention. Early intervention has become more and more essential in healthcare to enhance patient outcomes. Modern technologies help to achieve the essential goal of newborn screening. Accordingly, market players are coming up with new products to cater to the demand for new screening devices. For instance, in September 2023, MyLab introduced a revolutionary point-of-care newborn screening device named My NeoShield for newborn screening. The technology is expected to change the methods by that neonatal healthcare is provided by facilitating quicker, easier, and more economical screening, that can ultimately save lives and prevent diseases from developing into lifelong conditions. All seven tests used for newborn screening across the globe are supported by the device.

Segmental Outlook

The global newborn screening market is segmented on the technology, test type, and end-user. Based on the technology, the market is sub-segmented into tandem mass spectrometry, LC-MS/MS, pulse oximetry, DNA microarrays and NGS, enzyme based assays, and others. Based on the test type, the market is sub-segmented into blood spot screening (dried blood spot test), hearing screening (otoacoustic emissions and auditory brainstem response), pulse oximetry screening, CCHD, and others. Furthermore, based on the end-user, the market is sub-segmented into hospitals and birthing centers, NIUCs, diagnostic centers, researchers and scientists, and others. The hospitals and birthing centers subcategory is expected to capture a significant portion of the market share within the end-user segment. Rising disposable income along with a rise in patient hospitalization needs, increased prevalence of newborn diseases high-tech hospitals and healthcare infrastructure developments are additional factors propelling the market's growth.

The Hearing Screening Sub-Segment is Anticipated to Hold a Considerable Share of the Global Newborn Screening Market

Among the test types, the hearing screening sub-segment is expected to hold a considerable share of the global newborn screening market. The segmental growth is attributed to the prevalence of newborn hearing loss. The significance of newborn hearing screening programs is emphasized by the aforementioned rate. According to the National Institute of Health (NIH.gov), in October 2022, it occurs 1 to 1.5 times per 1000 live births when a neonate has severe or profound PBHL (loss of >60 dB [dB]). Bilateral mild to moderate hearing loss or unilateral hearing loss of any severity affects 1 to 2 more infants every 1000. The development of language and literacy, adult functioning, and quality of life are all significantly hindered by both severe and profound PBHL.

Regional Outlook

The global newborn screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of strong market competitors, advantageous reimbursement policies, and the availability of newborn screening programs.

The European Region is Expected to Grow at a Significant CAGR in the Global Newborn Screening Market

Among all regions, the European region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising improvement in diagnostic efficiency across the region. Newborns' whole genome sequencing is an effective diagnostic tool that can spot a variety of genetic abnormalities, even rare diseases. By enabling early detection and intervention, this degree of diagnostic accuracy can considerably improve the efficiency of newborn screening. The government along with the market players operating in the region are increasingly introducing such new diagnostic tools and initiatives to provide improved newborn healthcare services. For instance, in December 2022, the UK Government launched the Newborn Genomes Programme, a new study that examines the efficiency of whole genome sequencing in identifying uncommon disorders in newborn babies. In addition to the blood spot test, whole genome sequencing of newborns identified thousands of uncommon diseases and significantly improved the quality of life for children born with the aforementioned conditions. European market players and governments are creating favorable conditions for the rapid development of the newborn screening market by deploying different marketing strategies.

Furthermore, in September 2021, Public Health England (PHE), the UK National Screening Committee (UK NSC), NHS England, and NHS Improvement (NHSEI) launched an evaluation of newborn blood spot screening for severe combined immunodeficiency (SCID) in England.

Market Players Outlook

The major companies serving the newborn screening market include Hill-Rom Holdings, Inc., India Medtronic Pvt. Ltd., Integrated DNA Technologies, LifeCell International Pvt. Ltd., Masimo Corp.and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Eight taluk hospitals announced to launch a newborn screening. For which, the Mysuru-based All India Institute of Speech and Hearing (AIISH) collaborated with the Department of Health and Family Welfare for briefing the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening communication disorders in children. The initiative is introduced post recognizing the need for expanding the Newborn Screening Programme (NBS).

The Report Covers

Market value data analysis of 2022 and forecast to 2030.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global newborn screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying ‘who-stands-where’ in the market.